Skip to content Inauguração emGrand opening inInauguración en --d --h --m --s · Cadastro VIP ›· VIP sign-up ›· Registro VIP › Abrimos hoje · aguardeWe open today · hold onAbrimos hoy · aguarde Loja aberta! Entrar ›Store open! Enter ›¡Tienda abierta! Entrar ›
Eagle Pharma
Track order WhatsApp

KNOWLEDGE · COMPOUNDS

AOD-9604

MetabolicPreclinicalPubMed records: 15count from PubMed, not curated
Ask Eagle AI about this compound

Overview

O AOD-9604 é um fragmento modificado do hormônio do crescimento humano (aminoácidos 177-191 com tirosina adicionada). Retém a capacidade lipolítica do GH sem seus efeitos anabólicos, diabetogênicos ou na IGF-1, tornando-o específico para mobilização de gordura. Original in PT-BR

AOD-9604 is catalogued under Metabolic. 11 Eagle articles in this library reference this compound.

Category
Metabolic
Research stage
Preclinical — Pré-Clínico (Fase IIb inconclusiva) Original in PT-BR
PubMed records
15 (count from PubMed, not curated)
Eagle articles on this compound
11 Eagle articles

Mechanism

Fragmento GH (177-191) — mobiliza gordura sem efeitos anabólicos/diabetogênicos do GH Original in PT-BR

O AOD-9604 corresponde à região C-terminal do GH humano (resíduos 177-191) com uma tirosina extra na posição N-terminal. Este fragmento ativa o receptor beta-3 adrenérgico nos adipócitos, estimulando lipólise direta (quebra de triglicerídeos em ácidos graxos livres + glicerol). Diferentemente do GH completo, o AOD-9604 NÃO ativa o receptor GH/JAK2/STAT5, não eleva IGF-1, não causa resistência insulínica e não estimula crescimento de tecidos. Estudos in vitro demonstram que o AOD-9604 também inibe lipogênese (formação de nova gordura) e estimula oxidação de ácidos graxos. Há evidência preliminar de benefícios em osteoartrite via regeneração de cartilagem. Original in PT-BR

Eagle articles on this compound

Chemical information

CAS
221231-10-3
Molecular formula
C₇₈H₁₂₅N₂₃O₂₃S₂
Molecular weight
1817.12 g/mol
Sequence
YLRIVQCRSVEGSCGF
Amino acids
16 counted from the sequence above
Solubility
Água bacteriostática Original in PT-BR
Stability
Liofilizado: estável a -20°C. Reconstituído: 21 dias a 2-8°C Original in PT-BR
Half-life
~30 minutos Original in PT-BR
Bioavailability
Alta (SC) Original in PT-BR
Onset
2-4 semanas (lipólise) Original in PT-BR
Routes
SC

Research references

No individual dosing recommendation is given. Values are as recorded in the source, with species and route stated where known.

Third-party research score

35/ 100

Score assigned by the imported source, on its own scale and with no published methodology. Eagle does not compute it, does not verify it and does not endorse it. It appears here to preserve the record, not as an assessment.

  • AOD-9604 estimula lipólise in vitro comparável ao GH mas sem efeitos diabetogênicos Original in PT-BR

    PMID: 11713213Year: 2001Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

  • Propriedades condroprotetoras inesperadas — potencial para osteoartrite Original in PT-BR

    PMID: 15146725Year: 2004Species: Not recorded as a structured field in the source.Route: Not recorded as a structured field in the source.Duration: Not recorded as a structured field in the source.Purpose: Not recorded as a structured field in the source.

Safety

Commonly reported

  • Leve irritação no local de injeção
  • Cefaleia transitória (raro)

Serious

  • Sem efeitos adversos graves reportados em ensaios clínicos

Contraindications

  • Gravidez/amamentação
  • Câncer ativo

Warnings

  • Eficácia em humanos não comprovada de forma conclusiva
  • Dados limitados para uso prolongado

Original in PT-BR — This text was written in Brazilian Portuguese and is shown as recorded. Open the PT-BR page for AOD-9604.

Lab tests named in the source

  • Perfil lipídico
  • Glicemia de jejum
  • IGF-1 (confirmar ausência de elevação)
  • Função hepática

The source names the tests and nothing else: no reference values and no thresholds. None were added here. Interpreting a result is a clinical act and is not offered on this page.

Reported protocols

Recorded in the imported source as community protocols. They are NOT Eagle protocols, were not reviewed by Eagle, and are not a dosing recommendation, a prescription or clinical guidance. Values appear exactly as recorded, in the language they were written in.

Dosing summary as recorded

Dose Padrão
300mcg SC/dia Original in PT-BR
Range
250-600mcg/dia Original in PT-BR
Frequência
1x/dia (jejum) Original in PT-BR
Timing
Manhã em jejum (30min antes de comer) Original in PT-BR
Ciclo
12 semanas ON / 4 OFF Original in PT-BR

Vial sizes: 5mg — Peptide Calculator

Interactions

This section brings together two origins. The ones Eagle wrote come from its own curated library, one by one; the rest come from the imported reference material, which records one label and one comment per pair and no source. Neither kind carries a PMID, a population or model, or a degree of certainty. Eagle did not verify the imported ones and does not endorse them. «Compatible», «Caution» and «Avoid» are not an Eagle authorisation or prohibition, and none of this is medical advice.

Reported synergy

Compatible

Related

← Back to knowledge area